Immunological and inflammatory profiles in mild and severe cases of COVID-19.

Song JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, Cao WJ, Yang T, Dai XP, Wang SY, Xu RN, Jiang TJ, Li WG, Zhang DW, Zhao P, Shi M, Agrati C, Ippolito G, Maeurer M, Zumla A, Wang FS, Zhang JY. · 2020

Read Immunological and inflammatory profiles in mild and severe cases of COVID-19. by Song JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, Cao WJ, Yang T, Dai XP, Wang SY, Xu RN, Jiang TJ, Li WG, Zhang DW, Zhao P, Shi M, Agrati C, Ippolito G, Maeurer M, Zumla A, Wang FS, Zhang JY. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7343781.txt.

Introduction

Song and co-authors compare immune profiles in mild and severe COVID-19 in Nature Communications. Why some patients crash while others stay mild was a pressing early question. The team measured immune cells and inflammatory signals in both groups.

Severe cases showed deeper losses of helper and killer T cells and of natural killer cells. The T cells that remained were overactivated, carried high levels of blocking molecules, and in killer cells loaded up on toxic weapon proteins. Lung tissue from one patient who died held virus RNA plus dense infiltration by T cells and macrophages. The authors argue that this misdirected activation helps drive severe disease, and that immune targets offer a promising treatment route.

Catalog record

CREATORSong JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, Cao WJ, Yang T, Dai XP, Wang SY, Xu RN, Jiang TJ, Li WG, Zhang DW, Zhao P, Shi M, Agrati C, Ippolito G, Maeurer M, Zumla A, Wang FS, Zhang JY.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE38 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7343781

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Immunological and inflammatory profiles in mild and severe cases of COVID-19 By Jin-Wen Song, Chao Zhang, Xing Fan, Fan-Ping Meng, Zhe Xu, Peng Xia, Wen-Jing Cao, Tao Yang, Xiao-Peng Dai, Si-Yu Wang, Ruo-Nan Xu, Tian-Jun Jiang Published in: Nature Communications DOI: 10.1038/s41467-020-17240-2 ABSTRACT COVID-19 is associated with 5.1% mortality. Although the virological, epidemiological, clinical, and management outcome features of COVID-19 patients have been defined rapidly, the inflammatory and immune profiles require definition as they influence pathogenesis and clinical expression of COVID-19. Here we show lymphopenia, selective loss of CD4+ T cells, CD8+ T cells and NK cells, excessive T-cell activation and high expression of T-cell inhibitory molecules are more prominent in severe cases than in those with mild disease. CD8+ T cells in patients with severe disease express high levels of cytotoxic molecules. Histochemical studies of lung tissue from one fatality show sub-anatomical distributions of SARS-CoV-2 RNA and massive infiltration of T cells and macrophages. Thus, aberrant activation and dysregulation of CD8+ T cells occur in patients with severe COVID-19 disease, an effect that might be for pathogenesis of SARS-CoV-2 infection and indicate that immune-based targets for therapeutic interventions constitute a promising treatment for severe COVID-19 patients. INTRODUCTION As of 26th June 2020, the unprecedented global epidemic outbreak of novel Coronavirus Disease-2019 (COVID-19) has resulted in 9,296,202 laboratory-confirmed cases of SARS-CoV-2 infection reported from 210 countries to the WHO1. Of these, there have been 479,133 deaths (5.1% mortality). Whilst the virological, epidemiological, clinical, routine laboratory, imaging, and management outcome features of COVID-19 patients have been rapidly defined2–13, the immune and inflammatory profiles are not well understood. A wide spectrum of clinical manifestations occurs from mild to severe disease with extensive lung involvement leading to acute respiratory distress syndrome (ARDS) and death2–7,10,13. Severe lung disease with extensive alveolar damage and progressive respiratory failure leads to fatal outcomes3–5,7,11. Higher fatality rates occur in the elderly, and in individuals who have diabetes, co-morbidities and other causes of immunocompromise4. We recently reported a case where significant interstitial lymphocytic infiltrates in the lung tissue, lymphopenia, and overactivation of T cells in peripheral blood10. Inflammatory and immune responses are important for elimination of the infection, but may have a significant impact on SARS-CoV-2 pathogenesis, and may play a role in the expression of the clinical spectrum of COVID-19 disease. In this study, we perform a cross-sectional observational study of immunological and inflammatory markers and cells in 41 COVID-19 patients (29 with mild disease and 12 with severe disease including 2 fatal cases). We find COVID-19 patients in severe group are characterized by profound lymphopenia, strong T-cell activation, and increased expression of T-cell inhibitory molecules compared to mild group of patients. RESULTS Patient demographics and clinical features Forty-one patients with laboratory-confirmed acute COVID-19 disease were enrolled: 29 with mild disease and 12 with severe disease. Representative computed tomographic images are shown in Supplementary Fig. 1. Table 1 shows demographics and baseline characteristics of these patients. The median age was 39 years (IQR 33.5–50.0); 25 (61%) were male. The median time of symptom onset before admission was 5 days (IQR 4.0–9.0). Two patients (5%) died. Thirty-six patients (85%) reported fever before hospitalization. Signs and symptoms included myalgia or fatigue (46%), expectoration (32%), cough (27%), sore throat (17%), diarrhea (10%), shortness of breath (12%), rhinorrhea (2%), and chest pain (2%). The median age was significantly higher in severe group (50 years) compared to mild group (37 years, p = 0.0072, two-tailed Mann–Whitney U-test). The duration of symptoms before admission was also higher in severe group (10.5 vs. 5.0 days, p = 0.0064, two-tailed Mann–Whitney U-test). Symptoms such as expectoration, myalgia or fatigue, and shortness of breath were increased in severe group compared to mild group.Table 1Demographics and baseline characteristics of patients infected with SARS-CoV-2.Total (n = 41)Mild (n = 29)Severe (n = 12)p valueAge, years39.0 (33.5–50.0)37.0 (29.0–44.0)50.0 (39.75–85.0)0.0072Sex0.6308Men25 (61%)17 (59%)8 (67%)Women16 (39%)12 (41%)4 (33%)OnSet of symptom to hospital admission, days5.0 (4.0–9.0)5.0 (4.0–7.0)10.5 (5.0–12.25)0.0064Death2 (5%)02 (17%)0.0805Exposure to Wuhan24 (59%)18 (62%)6 (50%)0.4754Any comorbidity10 (24%)3 (10%)7 (58%)0.0011Hypertension5 (12%)1 (3%)4 (33%)0.0078Diabetes4 (10%)2 (7%)2 (17%)0.3374Malignancy1 (1%)01 (8%)0.2927Chronic liver disease3 (7%)1 (3%)2 (17%)0.2002Fever35 (85%)25 (86%)10 (83%)0.8128Highest temperature (°C)0.63<37.36 (15%)4 (14%)2 (17%)37.3–38.09 (22%)7 (24%)1 (8%)38.1–39.018 (44%)12 (41%)7 (58%)>39.08 (20%)6 (21%)2 (17%)Cough27 (66%)17 (59%)10 (83%)0.1289Expectoration13 (32%)6 (21%)7 (58%)0.0184Rhinorrhoea1 (2%)1 (3%)0>0.9999Myalgia or fatigue19 (46%)9 (31%)10 (83%)0.0022Nausea and vomiting000Sore throat7 (17%)5 (17%)2 (17%)0.9645Shortness of breath5 (12%)1 (3%)4 (33%)0.0078Chest pain1 (2%)01 (8%)0.2927Diarrhea4 (10%)4 (14%)00.1756Data are median (IQR), or n (%). p values comparing mild and severe are from two-tailed χ² test, two-tailed Fisher’s exact test, or two-tailed Mann–Whitney U-test. Laboratory findings Routine laboratory test results are shown in Table 2. There were no significant differences in the absolute number of leukocytes, neutrophils, and platelets counts between mild and severe group. The severe group exhibited a significantly lower absolute lymphocyte count than the mild group (p < 0.0001, two-tailed Mann–Whitney U-test). The severe group showed increased D-dimer (p = 0.0065, two-tailed Mann–Whitney U-test) and serum ferritin (p = 0.0024), and had a lower albumin levels (p = 0.0005, two-tailed Mann–Whitney U-test).Table 2Laboratory findings of hospitalized patients infected with SARS-CoV-2.Normal rangeTotal (n = 41)Mild (n = 29)Severe (n = 12)p valueLeukocytes count (×109 L−1)3.97–9.154.95 (4.02–6.68)4.95 (4.02–6.35)4.955 (3.9975–6.695)0.9718Neutrophils count (×109 L−1)2.0–7.02.93 (2.25–4.36)2.85 (2.24–3.75)3.715 (2.7425–5.04)0.2136Lymphocytes count (×109 L−1)0.80–4.001.31 (0.88–1.61)1.54 (1.17–1.82)0.775 (0.4925–1.0425)<0.0001Platelets count (×109 L−1)85.0–303.0170.0 (151.0–233.0)170.0 (151.0–218.0)170.0 (149.0–263.5)0.5854Hemoglobin (g L−1)131.0–172.0136.0 (128.0–148.0)140.0 (130.0–150.0)127.0 (113.5–147.25)0.114Activated partial thromboplastin time (s)23.0–42.030.4 (27.4–34.2)30.4 (28–34.7)30.1 (24.8–32.025)0.3382Prothrombin time (s)10.20–14.3011.9 (11.4–12.5)12.1 (11.5–12.5)11.65 (11.325–11.95)0.0922D-dimer (µg L−1)0.00–0.550.24 (0.17–0.53)0.23 (0.17–0.42)0.61 (0.245–0.985)0.0065Albumin (g L−1)35.0–55.039.0 (35.0–42.0)41.0 (38.0–43.0)34.5 (32.5–36.25)0.0005Alanine aminotransferase (U L−1)5.0–40.026.0 (15.0–40.0)24.0 (15.0–39.0)26.0 (14.75–70.75)0.6456Aspartate aminotransferase (U L−1)8.0–40.024.0 (19.0–35.0)25.0 (21.0–30.0)21.5 (18.0–55.0)0.5756Total bilirubin (μmol L−1)3.40–20.510.3 (7.3–14.7)9.5 (7.2–14.7)10.95 (8.825–14.2)0.5104Serum creatinine (μmol L−1)62.0–115.074.0 (69.0–85.0)80.0 (69.0–87.0)70.0 (67.0–79.0)0.0355Lactate dehydrogenase (U L−1)109.0–245.0212 (193–247)212 (193–247)210.5 (190.5–333.25)0.7185Interleukin-6 (pg mL−1)0.0–7.09.335 (5.383–23.8775)8.545 (5.395–16.865)18.695 (3.84–40.8175)0.6556C-reactive protein (mg L−1)0.068–8.207.4 (4.0–16.1)7.1 (4.0–10.4)10.955 (5.4125–36.55)0.1602Procalcitonin (ng mL−1)0.0–0.50.044 (0.035–0.065)0.0435 (0.034–0.0615)0.049 (0.0385–0.073)0.4569Erythrocyte sedimentation rate (mm h−1)0.0–15.012.5 (7.75–34.25)11.5 (7–19.75)26.5 (11.5–61)0.0699Serum ferritin (ng mL−1)30.0–400.0366.95 (187.5–538.025)306.8 (95.32–434.9)532 (419.7–837.6)0.0024Data are median (IQR). p values comparing mild and severe are from two-tailed Mann–Whitney U-test. T cells, B cells, and NK cells profiles The absolute numbers of CD3+ T cells, CD4+ T cells, CD8+ T cells, B cells, and NK cells are shown in Fig. 1a. The severe group had decreased numbers of CD3+ T cells, CD4+ T cells, CD8+ T cells, and NK cells compared to the group experienced a mild clinical presentation. 7 out of 9 (77.8%) patients exhibited decreased CD3+ T cell and CD4+ T cell counts, and 4 out of 9 (44.4%) patients had decreased CD8+ T cell and NK cell counts below normal levels. However, in the patient group with mild symptoms, 5 out of 18 (27.8%) patients exhibited decreased CD3+ T cell counts, 8 out of 18 (44.4%) patients exhibited decreased CD4+ T cell count. 2 out of 18 (11.1%) patients had decreased CD8+ T cell counts. NK cell count was in normal range for most mild patient (16/18), with two patients exhibited higher NK cells than normal. No statistical differences were observed in the frequencies of CD3+ T cells, CD4+ T cells, CD8+ T cells, and NK cells between mild and severe groups, except for that of B cells, which was increased in severe patients (p = 0.015, two-tailed Mann–Whitney U-test) (Fig. 1b).Fig. 1Absolute cell counts and percentages of peripheral lymphocyte subsets in SARS-CoV-2 infected patients.a Absolute cell counts and b percentages of CD3+ T

Read the complete text